Amneal Pharmaceuticals (AMRX) News Today $7.37 +0.07 (+0.96%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$7.18 -0.19 (-2.51%) As of 05/30/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Bank of America Corp DE grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 218.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 556,881 shares of the coMay 30 at 3:16 AM | marketbeat.comAmneal to Participate at Upcoming Investor Conferences in JuneMay 29 at 4:05 PM | globenewswire.comPhocas Financial Corp. Grows Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Phocas Financial Corp. boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 31.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,330,413 shares of the company's stock after purchasing an additional 315,223 shaMay 28, 2025 | marketbeat.comDeutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Deutsche Bank AG boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 50.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,886 shares of the company's stocMay 27, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Woodline Partners LPWoodline Partners LP lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 64.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 567,060 shares of the company's stock after selling 1,037,471 shaMay 26, 2025 | marketbeat.comMan Group plc Has $965,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Man Group plc grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 342.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 121,792 shares of the company's stock after buying an additional 94,263 sharesMay 26, 2025 | marketbeat.comNuveen Asset Management LLC Has $21.67 Million Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Nuveen Asset Management LLC cut its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,735,743 shares of the company's stock after sellingMay 26, 2025 | marketbeat.comSherbrooke Park Advisers LLC Has $97,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Sherbrooke Park Advisers LLC reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 81.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,274 shares of the company's stock after selling 54,293 sharesMay 24, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 209.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 168,194 shares of the companMay 22, 2025 | marketbeat.comGotham Asset Management LLC Acquires 40,224 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Gotham Asset Management LLC increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 84.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 87,883 shares of the company's stock afterMay 21, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Ameriprise Financial Inc. lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,539,247 shares of the company's stock after selliMay 21, 2025 | marketbeat.comNorthern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Northern Trust Corp lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,777,283 shares of the company's stock after purchasing an additional 156,6May 18, 2025 | marketbeat.comQuantedge Capital Pte Ltd Buys New Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Quantedge Capital Pte Ltd bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 75,500 shares of the company's stock, valued atMay 17, 2025 | marketbeat.comAMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline ProgressMay 16, 2025 | finance.yahoo.comBalyasny Asset Management L.P. Invests $1.37 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Balyasny Asset Management L.P. purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 172,313 shares of the company's stock, valued at approMay 16, 2025 | marketbeat.comAmneal Gets FDA Nod For Self-Administrable Migraine InjectionMay 15, 2025 | msn.comUS FDA approves Amneal's self-administered migraine treatmentMay 15, 2025 | msn.comUS FDA approves Amneal's migraine treatmentMay 15, 2025 | reuters.comAmneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in AdultsMay 15, 2025 | globenewswire.comAmneal Pharmaceuticals (NASDAQ:AMRX) Downgraded to "Buy" Rating by StockNews.comStockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday.May 15, 2025 | marketbeat.comAre Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock?May 10, 2025 | msn.comAmneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.May 8, 2025 | globenewswire.comAmneal Pharmaceuticals (NASDAQ:AMRX) Trading Down 5.7% - What's Next?Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 5.7% - Here's WhyMay 7, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Dimensional Fund Advisors LPDimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,991,702 shares of tMay 7, 2025 | marketbeat.comAquatic Capital Management LLC Buys New Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Aquatic Capital Management LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 57,610 shares of the company's stock,May 5, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Trimmed by Wells Fargo & Company MNWells Fargo & Company MN lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 56.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 77,973 shares of the company's stock after selling 99,862 shares durinMay 5, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Announces Earnings ResultsAmneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) released its quarterly earnings results on Friday. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%.May 4, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance. The company provided EPS guidance of 0.650-0.70 for the period, compared to the consensus estimate of 0.680. The company also issued revenue guidance of $3.0 billionillion-$3.1 billionillion, compared to the consensus estimate of $3.0 billionillion.May 4, 2025 | marketbeat.comVoleon Capital Management LP Acquires New Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Voleon Capital Management LP bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 55,962 shares of the company's stock, valued at approximately $443,00May 4, 2025 | marketbeat.comPDT Partners LLC Buys Shares of 79,169 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)PDT Partners LLC purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 79,169 shares of the company's stock, valued at approMay 4, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2025 Earnings Call TranscriptMay 3, 2025 | insidermonkey.com46,512 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Nebula Research & Development LLCNebula Research & Development LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 46,512 shares of the companyMay 3, 2025 | marketbeat.comFirst Trust Advisors LP Has $5.33 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)First Trust Advisors LP boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 672,403 shares of the companyMay 3, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comAmneal Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 2, 2025 | seekingalpha.comAmneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%May 2, 2025 | finance.yahoo.comAmneal Reports First Quarter 2025 Financial ResultsMay 2, 2025 | businesswire.comBarclays PLC Purchases 56,110 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Barclays PLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 18.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 352,494 shares of the company's stock after buying an additional 56,110 shares during the peMay 2, 2025 | marketbeat.com2AMRX : Examining the Future: Amneal Pharmaceuticals's Earnings OutlookMay 1, 2025 | benzinga.comAmneal (AMRX) To Report Earnings Tomorrow: Here Is What To ExpectMay 1, 2025 | msn.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is Nantahala Capital Management LLC's 10th Largest PositionNantahala Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 37.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,665,529 shares ofApril 30, 2025 | marketbeat.com371,996 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Raymond James Financial Inc.Raymond James Financial Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 371,996 shares of the company's stock, valued at approximately $2,946,April 30, 2025 | marketbeat.comOxford Asset Management LLP Invests $440,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Oxford Asset Management LLP bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 55,526 shares of the company'April 29, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Walleye Capital LLCWalleye Capital LLC lessened its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 70.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,979 shares of the company's stock after selling 92,688 shares during tApril 27, 2025 | marketbeat.com2 Reasons to Avoid AMRX and 1 Stock to Buy InsteadApril 24, 2025 | finance.yahoo.comBlackBarn Capital Partners LP Grows Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)BlackBarn Capital Partners LP increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 18.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,850,000 shares of the company's stock afteApril 24, 2025 | marketbeat.comMariner LLC Acquires 413,268 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Mariner LLC raised its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3,749.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 424,291 shares of the company's stock after buying an additional 413,2April 23, 2025 | marketbeat.com165,916 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Jump Financial LLCJump Financial LLC bought a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 165,916 shares of the company's stock, valued at approximately $1,314,000. JuApril 22, 2025 | marketbeat.comRenaissance Technologies LLC Lowers Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Renaissance Technologies LLC cut its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 686,500 shares of the company's stockApril 22, 2025 | marketbeat.comInvesco Ltd. Has $15.11 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Invesco Ltd. decreased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 17.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,907,246 shares of the company's stock after selling 389,951 sharesApril 22, 2025 | marketbeat.com Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Media Mentions By Week AMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼1.440.88▲Average Medical News Sentiment AMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼85▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News Today RVMD News Today BPMC News Today BBIO News Today ELAN News Today VRNA News Today TLX News Today GRFS News Today TGTX News Today LEGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMRX Stock Free AMRX Stock Alerts